NRx Pharmaceuticals closes $22.3M public offering of common stock at $3.50/share

NRX Pharmaceuticals, Inc.

Priced 5,714,286 shares at $3.50; underwriters' option for 857,142 shares exercised, gross proceeds $22.3M.
Net proceeds estimated ~$21.6M after underwriting discounts and expenses; funds working capital and growth.
BTIG acted as lead bookrunner; Lucid Capital Markets as joint bookrunner.
Offering led by B Group Capital, with participation from Columbia Threadneedle, Corbets Capital, Venture 76, and Mossrock Capital.
Shares issued under effective S-3 shelf (No. 333-288205); closed June 4, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NRX Pharmaceuticals, Inc. entered into Underwriting Agreement with BTIG, LLC valued at approximately $18.8 million (or $21.6 million, if the Underwriters’ option to purchase additional sh (effective 2026-06-03).

Action: entry
Agreement: underwriting
Counterparty: BTIG, LLC
Value: approximately $18.8 million (or $21.6 million, if the Underwriters’ option to purchase additional sh
Effective: 2026-06-03

Exact text from the filing

On June 3, 2026, NRx Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with BTIG, LLC, as representative of the several underwriters listed in Schedule A thereto (the “ Underwriters ”) in connection with a public offering of an aggregate of 5,714,286 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), by the Company at a price to the public of $3.50 per share (the “ Offering ”).

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-019576

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.